系统性红斑狼疮中糖皮质激素使用负担的深度解读
本文综述了系统性红斑狼疮(SLE)中糖皮质激素(GCs)使用理念的转变:从过去认为GCs不可撤停,转变为当前推荐长期维持剂量不超过泼尼松等效5 mg/天,并可在缓解期尝试撤停。证据显示较高GC剂量与感染、心血管事件及其他损害相关,且撤停在许多缓解期SLE患者中可行。
要点
- 当前推荐长期使用的泼尼松等效剂量限制在≤5 mg/天。
- 证据将较高GC剂量与感染、心血管事件及其他损害相关联。
- 许多处于缓解期的SLE患者撤停GCs是可行的。
核心结论
- 过去认为GCs因恐惧严重复发而绝不能撤停的教条已被证明错误,当前策略鼓励逐渐减量至0并质疑是否需启动GCs。
- 当前推荐长期使用的泼尼松等效剂量限制在≤5 mg/天,全球经验提示该限度是合理的。
研究设计与样本
- 本文为综述,总结了过去数十年对SLE患者使用GCs态度变化的证据。
主要发现
- 大量证据将较高GC剂量与感染、心血管事件及其他损害相关联。
- 越来越多的研究表明,许多处于缓解期的SLE患者撤停GCs是可行的。
- 尽管观察性数据存在适应证混杂的方法学顾虑,过去数十年的全球经验提示每日5 mg的限度是合理的。
关键数值与推荐
- 当前推荐长期使用的泼尼松等效剂量限制在≤5 mg/天。
临床怎么用
- 对SLE患者应积极逐渐减量GCs至0,并质疑是否需启动GCs。
- 长期维持治疗应将泼尼松等效剂量控制在≤5 mg/天。
- 当前策略和新型药物使许多SLE患者能在泼尼松≤5 mg/天的情况下维持缓解或低疾病活动度。
局限性
- 观察性数据固有地易受适应证混杂影响,存在方法学顾虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The attitude towards using glucocorticosteroids (GCs) for the management of patients with systemic lupus erythematosus (SLE) has undergone drastic changes over the last decades. While the role of GCs for the rapid control of inflammation is uncontested, the former 'dogma' that GCs must never be withdrawn due to fear of severe flares was proven wrong and replaced by a strategy that invites both tapering GCs to 0 and questioning whether they even need to be initiated at all in individual patients. Moreover, the daily prednisone equivalent dose acceptable for long-term use is limited to ≤ 5 mg in current recommendations. These changes are a consequence of a substantial body of evidence that links higher GC doses to infections, cardiovascular events and other damage, and an increasing number of studies showing that GC withdrawal is feasible in many SLE patients who are in remission. Despite methodological concerns, with observational data inherently prone to confounding by indication, the worldwide experience of the last decades suggests that the limit of 5 mg daily is justified. Moreover, current strategies and novel medications have made it a reality for many SLE patients, to actually maintain the goal of remission or low disease activity on not >5 mg of prednisone per day.
引用
- Fanouriakis A, Aringer M. The burden of steroid use in systemic lupus erythematosus. Rheumatology (Oxford). 2026. PMID: 42378447. doi:10.1093/rheumatology/keag344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。